Form 8-K Revolution Medicines, For: Aug 26
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Revolution Medicines prices RASONQUE at $39,800 per month
August 26, 2026 1:54 PM EDT(Updated - August 26, 2026 2:04 PM EDT)
The U.S. Food and Drug Administration approved Revolution Medicines' (NASDAQ: RVMD) RASONQUE (daraxonrasib) on August 26, 2026, for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for... More
